Status:
COMPLETED
Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Lung Cancer
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lung cancer is a malignant tumor that has transformed from a single cancer disease into one of the most striking global health problems. Lung cancer has an insidious onset, and most patients are first...
Detailed Description
A two-arm, assessor-blind randomized controlled trial will be conducted to investigate the effects of ACT on advanced lung cancer patients compared to usual care. Participants in the same ward will be...
Eligibility Criteria
Inclusion
- aged 18 or over;
- diagnosed with stage III or stage IV lung cancer by pathological section or cytology;
- experienced unexplained fatigue syndrome: the score of 3 or more on the Fatigue Symptom Inventory (FSI); and
- able to provide informed consent and effectively collect data.
Exclusion
- diagnosed with cognitive dysfunction or other mental illnesses that may interfere with their completion of treatment;
- who are with a life expectancy \<3 months, or whose physical conditions are considered ineligible for the present study based on the physician's judgment; and
- who are receiving or have just completed other lung cancer-related intervention programs within the last six months
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 7 2022
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04869267
Start Date
July 1 2021
End Date
January 7 2022
Last Update
October 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangya Hospital Central South University
Changsha, Hunan, China